Clinical OMICS

MAR-APR 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 11 of 51

10 Clinical OMICs March/April 2018 Publisher & CEO MARY ANN LIEBERT President MARIANNE RUSSELL Group Publisher SANDE GIACCONE Editor in Chief CHRIS ANDERSON EVP, Strategic Development KEVIN DAVIES Commercial Director BILL LEVINE Production Editor ROBERT M. REIS Senior Editor KEVIN MAYER Technical Editor JEFFREY S. BUGULISKIS, PH.D. Senior News Editor ALEX PHILIPPIDIS Chief Copy Editor STEVEN HERNACKI Contributing Editors HELEN ALBERT, MALORYE BRANCA, MEGHAAN FERREIRA, CAMILLE MOJICA REY Art Director JAMES LAMBO Online Product Manager THOMAS MATHEW Associate Director of Brand Marketing JENNIFER GATTI Online Editorial Supervisor KATHERINE VUKSANAJ Design & Layout DIANNE PAULET, BYRON DUQUE Advertising Sales Manager REBECCA SHUMBATA US West & Asia Pacific ( / 617-435-4786) Advertising Sales Manager STAN KASHINE US East, UK, & Europe ( / 516-626-2813) List Sales SCOTT PERILLO ( / 914-740-2178) Sales Administrator FALLON MURPHY Advertising Material WANDA SANCHEZ ( Clinical OMICs Advisory Board DANIEL H. FARKAS, PH.D., HCLD Chief Clinical Laboratory Officer, Celmatix JEFFREY GIBBS, J.D. Director, Hyman, Phelps, and McNamara PETER HARRSCH, PH.D. Executive Clinical/Forensic Specialist, Waters Corp. ROGER KLEIN, M.D., J.D. Medical Director, Molecular Pathology, Cleveland Clinic JASON PARK, M.D., PH.D. Assistant Professor, Dept. of Pathology, University of Texas Southwestern Medical Center STEPHEN C. PEIPER, M.D. Professor & Chair, Dept. of Pathology, Anatomy & Cell Biology, Thomas Jefferson University AMIT RASTOGI Senior Vice President, Strategy, Growth, and Innovation, Inova DAVID SMITH, PH.D. Professor of Laboratory Medicine and Pathology, Mayo Clinic KIMBERLY STRONG, PH.D. Director, Program in Genomics and Ethics, Medical College of Wisconsin LARRY WORDEN Vice President and Senior Partner, Market Diagnostics International The views, opinions, findings, conclusions, and recommenda- tions set forth in any article in Clinical OMICs are solely those of the authors of those articles and do not necessarily reflect the views, policy, or position of Clinical OMICs, its Publisher, or its editorial staff and should not be attributed to any of them. All advertisements are subject to review by the Publisher. The acceptance of advertisements does not constitute an endorse- ment of the product or service advertised. Clinical OMICs (ISSN-2334-1351) is published online bimonthly by GEN Publishing, 140 Huguenot St., 3rd Floor, New Rochelle, NY 10801-5215. For subscription information go to: Copyright © 2018 by GEN Publishing, New Rochelle, NY M uch is made of health disparities in the United States, and the causes are multivariate involving some combination of lack of access, socio-eco- nomic status, lack of health insurance, diet, and lifestyle. The unfortunate reality is that like most of life, when it comes to healthcare—at least in this country—there are haves and have nots. This contrast is especially stark in cancer care, where those fortunate enough to live within shouting distance of an urban center or top-notch aca- demic medical center can get the best care, including precision can- cer treatments guided by genomics. It's a level of care that is simply not available to the majority of cancer patients. And while the catchphrase "the democratization of cancer care" rolls off the tongue with the latest gee-whiz advance in genomic-guided precision treatment, too many people—including myself—blithely discuss this so-called democratization without a thought to what that practically entails. That's not the case with it comes to Ed Liu and has team at The Jackson Lab- oratory (JAX), and the affiliated Maine Cancer Genomics Initiative (MCGI). Liu, who joined JAX as CEO in 2012, has led a transformation of the orga- nization, most notably the creation of The Jackson Laboratory for Genomic Medicine opened three-and-a-half years ago in Farmington, CT. With MCGI, Liu has made clear his intentions. "My view was that unless we had a regulatory-compliant unit that brought our technologies to the most proximate place of human contact, the clinic, we would forever be an ivory tower," he says. The first investment of $12 million dollars from JAX, in conjunction with a private foundation grant of $8.4 million, established MCGI. Its mission: to work with all the hospital systems and oncologists in Maine; provide free cancer genomic testing to 1,800 cancer patients; build an educational and consultative framework for genomic medicine; and create an IT and technology backbone to deliver it all to oncologists and their patients, regardless of location. The five-year initiative is set to conclude in 2021 at which time MCGI will have collected data not only on the health outcomes of patients and the economic benefits of making genomic testing an integral part of cancer care, but also data on the doctors and how the tools MCGI provided transformed their practices. The clinicians, Liu said, "are not just recipients, but participants in an enterprise. Our study is not just the delivery of the product—this test to the patients—but the doctors themselves are also test subjects." In short, the initiative hopes to discover methods of mitigating disparities in cancer treatment, in a broad geographic area, and across a range of socio-eco- nomic populations, leveraging both diagnostic and telemedicine technologies. If successful, the model could be deployed in other areas across the country. This is what democratization of cancer care could look like. Mitigating Cancer Care Disparities FROM THE EDITOR Chris Anderson Editor in Chief

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2018